中新网7月30日电（赵方园）近日，一家医药企业在国家药品集采中因违规被重罚，需退回高达2.66亿元的损失，这一金额已超过其去年全年的净利润。
据公开资料显示，该医药企业全资子公司广州一品红制药有限公司因在第七批国家组织药品集中带量采购中存在违规行为，违反了《全国药品集中采购文件》中的相关规定。根据文件17.4条款，该公司需承担给采购方造成的损失共计2.66亿元，并退回全部损失金额。
据了解，此次处罚是中国医药行业进入集采后，违约处罚最严重、罚金最高的案例。盐酸溴己新注射液是该次集采供应规模最大的品种之一，最高有效申报价格为22.9元/支，最终平均中选价格为17.95元/支，下降幅度为22%，是降价幅度最小的品种之一。
一品红旗下盐酸溴己新注射液以17.88元的中标价获得第七批国家药品集采22%的约定采购额度。石家庄四药以16.97元/支的最低价格获得了最大约定采购规模。
然而，今年4月17日，国家组织药品联合采购办公室发布公告称，包括溴己新注射剂在内的4个品种被群众举报，存在投标价格异常情形，被该办约谈。4月29日，国家组织药品联合采购办公室发布公告称，收到国采部分中选企业自主降价承诺函，涉及溴己新注射剂等4个品种。
根据一品红2023年财报，公司去年实现营业收入25.03亿元，同比增长9.79%；归母净利润1.85亿元，同比减少36.49%。因此，2.66亿的退款金额已超出一品红去年全年的净利润。
截至目前，中新健康致电上述4家公司，但截至发稿，公司官网电话显示空号或无法接通。
此次重罚再次提醒医药企业在参与国家药品集采时，必须严格遵守相关规则和规定，确保公平竞争，维护市场秩序。同时，这也为其他企业敲响了警钟，确保在未来的集采中能够合法合规地参与竞争。
英语如下：
News Title: “A Red One Inc. Faces Heavy Penalty for Bid-rigging Violation, Must Return Over 266 Million Yuan in Losses Exceeding Last Year’s Profit”
Keywords: Severe Penalty for Breach, A Red One, Over Profit
News Content:
China News Service, July 30, 2023 (Hao Fangyuan) – Recently, a pharmaceutical company was severely penalized for violating the rules during the national drug procurement, requiring it to return a loss of 266 million yuan. This amount exceeds its full-year net profit for last year.
According to public data, the wholly-owned subsidiary of the pharmaceutical company, Guangzhou A-One Red Pharmaceutical Co., Ltd., was found to have engaged in violations during the seventh batch of national organized procurement of drugs, violating the relevant provisions of the “National Drug Centralized Procurement Documents.” According to Article 17.4 of the documents, the company is required to bear a total loss of 266 million yuan to the purchaser and return the full amount of the loss.
It is understood that this penalty is the most severe and largest fine in the pharmaceutical industry for breach of contract since the industry entered the centralized procurement. Salbutamol sulfate injection is one of the largest varieties supplied in this batch of centralized procurement, with a highest effective bid price of 22.9 yuan per vial and an average winning price of 17.95 yuan per vial, a decrease of 22%, making it one of the smallest price reductions.
A-One Red’s salbutamol sulfate injection won 22% of the agreed procurement quota in the seventh batch of national drug procurement at a winning price of 17.88 yuan per vial. Shijiazhuang Sifang Pharmaceutical won the largest agreed procurement scale at a price of 16.97 yuan per vial.
However, on April 17, the National Organization for Drug Joint Procurement issued a notice stating that four varieties, including salbutamol sulfate injection, were reported by the public to have abnormal bidding prices and were called for a meeting. On April 29, the National Organization for Drug Joint Procurement issued a notice stating that it had received a voluntary price reduction commitment letter from some selected enterprises involved in the National Procurement, affecting four varieties including salbutamol sulfate injection.
According to A-One Red’s 2023 financial report, the company achieved a revenue of 2.503 billion yuan last year, a year-on-year increase of 9.79%, and a net profit attributable to shareholders of 185 million yuan, a year-on-year decrease of 36.49%. Therefore, the 266 million yuan in refunds exceeds A-One Red’s full-year net profit last year.
As of the time of this report, China News Service has made calls to the four companies mentioned above, but as of the time of submission, the official website phone numbers show no response or unreachable.
This heavy penalty once again reminds pharmaceutical companies to strictly abide by relevant rules and regulations when participating in national drug procurement, ensuring fair competition and maintaining market order. It also serves as a warning to other companies, ensuring they can participate in future procurements legally and in compliance with regulations.
【来源】http://www.chinanews.com/cj/2024/07-30/10260342.shtml
Views: 2